SMO and neoplasm: Tang and collaborators identified the small molecule JQ1 [(S)-(+)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate] as a BRD4 inhibitor, capable of indirectly affecting the GLI1 activity and suppressing the tumor growth in several HH-dependent mouse models (BCC, MB, and atypical teratoid rhabdoid tumor) resistant to SMO antagonists (Tang et al., 2014).